State Street Corp Has $7.50 Million Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

State Street Corp raised its stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 5.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 469,601 shares of the company’s stock after purchasing an additional 24,385 shares during the period. State Street Corp’s holdings in Entrada Therapeutics were worth $7,504,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. The Manufacturers Life Insurance Company boosted its holdings in shares of Entrada Therapeutics by 3.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 57,098 shares of the company’s stock worth $814,000 after buying an additional 2,146 shares during the period. US Bancorp DE bought a new stake in shares of Entrada Therapeutics during the third quarter worth approximately $42,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Entrada Therapeutics by 34.7% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,156 shares of the company’s stock valued at $226,000 after purchasing an additional 3,644 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Entrada Therapeutics by 25.3% during the second quarter. Rhumbline Advisers now owns 36,940 shares of the company’s stock worth $526,000 after purchasing an additional 7,452 shares during the period. Finally, Acadian Asset Management LLC lifted its holdings in Entrada Therapeutics by 135.1% during the 2nd quarter. Acadian Asset Management LLC now owns 13,367 shares of the company’s stock worth $190,000 after purchasing an additional 7,682 shares during the last quarter. 86.39% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, major shareholder Bioventures 2018 L.P. Mpm sold 22,935 shares of Entrada Therapeutics stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $20.77, for a total value of $476,359.95. Following the transaction, the insider now directly owns 4,402,849 shares of the company’s stock, valued at $91,447,173.73. This trade represents a 0.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Kory James Wentworth sold 8,637 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $19.98, for a total value of $172,567.26. Following the sale, the chief financial officer now owns 73,849 shares of the company’s stock, valued at $1,475,503.02. The trade was a 10.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 42,281 shares of company stock valued at $861,999 over the last quarter. 7.59% of the stock is owned by company insiders.

Entrada Therapeutics Stock Performance

NASDAQ:TRDA opened at $17.41 on Friday. The company has a market cap of $651.48 million, a price-to-earnings ratio of 10.95 and a beta of -0.18. Entrada Therapeutics, Inc. has a fifty-two week low of $11.35 and a fifty-two week high of $21.79. The stock has a fifty day moving average price of $18.53 and a 200-day moving average price of $16.74.

Analyst Ratings Changes

A number of research analysts have commented on TRDA shares. Oppenheimer upped their price objective on Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, November 6th. HC Wainwright raised their price target on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Roth Mkm initiated coverage on shares of Entrada Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $29.00 price objective for the company. Finally, Roth Capital upgraded shares of Entrada Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.